You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>IMS</strong> COM PANY PRO FILES TAKEDA<br />
� Earnings per Share<br />
In the year end ing March 31 2008, earn ings per share at Takeda grew by 8.5% to Yen419.0 from<br />
Yen386.0 the pre vi ous year.<br />
Yen<br />
450.0<br />
400.0<br />
350.0<br />
300.0<br />
250.0<br />
200.0<br />
150.0<br />
100.0<br />
50.0<br />
0.0<br />
Source: Takeda Annual <strong>Report</strong>s<br />
� R&D Costs<br />
Earnings Per Share<br />
Spend ing on R&D in creased by 42.7% in the year to March 31 2008 to reach Yen276 bil lion, or 20.1% of<br />
sales, up from Yen193 bil lion (14.8% of sales) in the pre vi ous year. This in crease was par tially due to li -<br />
cense fees paid to Amgen.<br />
Yen billions<br />
300<br />
250<br />
200<br />
150<br />
100<br />
50<br />
0<br />
Source: Takeda Annual <strong>Report</strong>s<br />
2004 2005 2006 2007 2008<br />
� Sales by Business Sector<br />
R&D Costs<br />
2004 2005 2006 2007 2008<br />
Takeda’s busi ness was pre vi ously clas si fied into four seg ments, but since April 2003 the re struc tur ing and<br />
divestments of sev eral non-core busi nesses have left the firm with just two seg ments: Pharmaceuticals<br />
and Other. Within Pharmaceuticals, the com pany splits sales out fur ther into Eth i cal Drugs (split again<br />
into Do mes tic and Over seas) and Con sumer Healthcare. The Other seg ment rep re sents the man u fac ture<br />
and sales of lab o ra tory chem i cals and clin i cal di ag nos tic agents, spe cialty chem i cals, beverages and food,<br />
among others.<br />
© 2009 <strong>IMS</strong> Health In cor po rated or its af fil i ates Page 16